Siegfried set to buy custom synthesis and API units from BASF for $300m
By Dan Stanton+, 07-May-2015
BASF says it remains committed to the pharma industry despite plans to divest its custom synthesis business and around 100 APIs and intermediates to Siegfried Holding.